




版權(quán)說(shuō)明:本文檔由用戶提供并上傳,收益歸屬內(nèi)容提供方,若內(nèi)容存在侵權(quán),請(qǐng)進(jìn)行舉報(bào)或認(rèn)領(lǐng)
文檔簡(jiǎn)介
1、Medical GeneticsMedical Genetics Genes, which are carried on chromosomes, are the basic physical and functional units of heredity. Genes are specific sequences of bases that encode instructions on how to make proteins. Medical Genetics Although genes get a lot of attention, its the proteins that per
2、form most life functions and even make up the majority of cellular structures. Medical Genetics When genes are altered so that the encoded proteins are unable to carry out their normal functions, genetic disorders can result.Medical Genetics Gene therapy is a technique for correcting defective genes
3、 responsible for disease development. Medical Genetics Researchers may use one of several approaches for correcting faulty genes:A normal gene may be inserted into a nonspecific location within the genome to replace a nonfunctional gene. This approach is most common.An abnormal gene could be swapped
4、 for a normal gene through homologous recombination.The abnormal gene could be repaired through selective reverse mutation, which returns the gene to its normal function.The regulation (the degree to which a gene is turned on or off) of a particular gene could be altered. Medical Genetics In most ge
5、ne therapy studies, a normal gene is inserted into the genome to replace an abnormal, disease-causing gene. Medical Genetics A carrier molecule called a vector must be used to deliver the therapeutic gene to the patients target cells. Currently, the most common vector is a virus that has been geneti
6、cally altered to carry normal human DNA. Medical Genetics Viruses have evolved a way of encapsulating and delivering their genes to human cells in a pathogenic manner. Medical Genetics Scientists have tried to take advantage of this capability and manipulate the virus genome to remove disease-causin
7、g genes and insert therapeutic genes.Medical Genetics Target cells such as the patients liver or lung cells are infected with the viral vector. The vector then unloads its genetic material containing the therapeutic human gene into the target cell. Medical Genetics The generation of a functional pro
8、tein product from the therapeutic gene restores the target cell to a normal state. Medical GeneticsTo reverse disease caused by genetic damage, researchers isolate normal DNA and package it into a vector, a molecular delivery truck usually made from a disabled virus. Doctors then infect a target cel
9、l usually from a tissue affected by the illness, such as liver or lung cellswith the vector. The vector unloads its DNA cargo, which then begins producing the missing protein and restores the cell to normal.Medical GeneticsA. Some of the different types of viruses used as gene therapy vectors(1) Ret
10、roviruses A class of viruses that can create double-stranded DNA copies of their RNA genomes. These copies of its genome can be integrated into the chromosomes of host cells. Human immunodeficiency virus (HIV) is a retrovirus.Medical Genetics(2)Adenoviruses A class of viruses with double-stranded DN
11、A genomes that cause respiratory, intestinal, and eye infections in humans. The virus that causes the common cold is an adenovirus.(3)Adeno-associated viruses A class of small, single-stranded DNA viruses that can insert their genetic material at a specific site on chromosome 19.(4)Herpes simplex vi
12、ruses A class of double-stranded DNA viruses that infect a particular cell type, neurons. Herpes simplex virus type 1 is a common human pathogen that causes cold sores. Medical GeneticsMedical GeneticsMedical GeneticsMedical Genetics Besides virus-mediated gene-delivery systems, there are several no
13、nviral options for gene delivery. The simplest method is the direct introduction of therapeutic DNA into target cells. This approach is limited in its application because it can be used only with certain tissues and requires large amounts of DNA.Medical Genetics Another nonviral approach involves th
14、e creation of an artificial lipid sphere with an aqueous core. This liposome, which carries the therapeutic DNA, is capable of passing the DNA through the target cells membrane.Medical Genetics Therapeutic DNA also can get inside target cells by chemically linking the DNA to a molecule that will bin
15、d to special cell receptors. Medical Genetics Once bound to these receptors, the therapeutic DNA constructs are engulfed by the cell membrane and passed into the interior of the target cell. This delivery system tends to be less effective than other options.Medical Genetics Researchers also are expe
16、rimenting with introducing a 47th artificial human chromosome into target cells. This chromosome would exist autonomously alongside the standard 46 -not affecting their workings or causing any mutations. Medical Genetics It would be a large vector capable of carrying substantial amounts of genetic c
17、ode, and scientists anticipate that, because of its construction and autonomy, the bodys immune systems would not attack it. A problem with this potential method is the difficulty in delivering such a large molecule to the nucleus of a target cell. Medical Genetics Current gene therapy is experiment
18、al and has not proven very successful in clinical trials. Medical Genetics Little progress has been made since the first gene therapy clinical trial began in 1990. In 2019, gene therapy suffered a major setback with the death of 18-year-old Jesse Gelsinger. Medical Genetics Jesse was participating i
19、n a gene therapy trial for ornithine transcarboxylase deficiency (OTCD). He died from multiple organ failures 4 days after starting the treatment. His death is believed to have been triggered by a severe immune response to the adenovirus carrier. Medical Genetics Another major blow came in January 2
20、019, when the FDA (USA) placed a temporary halt on all gene therapy trials using retroviral vectors in blood stem cells. Medical Genetics FDA (USA) took this action after it learned that a second child treated in a French gene therapy trial had developed a leukemia-like condition. Medical Genetics B
21、oth this child and another who had developed a similar condition in August 2019 had been successfully treated by gene therapy for X-linked severe combined immunodeficiency disease (X-SCID), also known as bubble baby syndrome.Medical Genetics FDAs Biological Response Modifiers Advisory Committee (BRM
22、AC) met at the end of February 2019 to discuss possible measures that could allow a number of retroviral gene therapy trials for treatment of life-threatening diseases to proceed with appropriate safeguards. FDA has yet to make a decision based on the discussions and advice of the BRMAC meeting.Medi
23、cal GeneticsA. Short-lived nature of gene therapy Before gene therapy can become a permanent cure for any condition, the therapeutic DNA introduced into target cells must remain functional and the cells containing the therapeutic DNA must be long-lived and stable. Medical Genetics Problems with inte
24、grating therapeutic DNA into the genome and the rapidly dividing nature of many cells prevent gene therapy from achieving any long-term benefits. Patients will have to undergo multiple rounds of gene therapy.Medical GeneticsB. Immune response Anytime a foreign object is introduced into human tissues
25、, the immune system is designed to attack the invader. Medical Genetics The risk of stimulating the immune system in a way that reduces gene therapy effectiveness is always a potential risk. Medical Genetics Furthermore, the immune systems enhanced response to invaders it has seen before makes it di
26、fficult for gene therapy to be repeated in patients.Medical GeneticsC. Problems with viral vectors Viruses, while the carrier of choice in most gene therapy studies, present a variety of potential problems to the patient -toxicity, immune and inflammatory responses, and gene control and targeting is
27、sues. Medical Genetics In addition, there is always the fear that the viral vector, once inside the patient, may recover its ability to cause disease.Medical GeneticsD. Multigene disorders Conditions or disorders that arise from mutations in a single gene are the best candidates for gene therapy. Me
28、dical Genetics Unfortunately, some the most commonly occurring disorders, such as heart disease, high blood pressure, Alzheimers disease, arthritis, and diabetes, are caused by the combined effects of variations in many genes. Medical Genetics Multigene or multifactorial disorders such as these woul
29、d be especially difficult to treat effectively using gene therapy. Medical Genetics University of California, Los Angeles, research team gets genes into the brain using liposomes coated in a polymer call polyethylene glycol (PEG). The transfer of genes into the brain is a significant achievement bec
30、ause viral vectors are too big to get across the blood-brain barrier. This method has potential for treating Parkinsons disease. Medical Genetics RNA interference or gene silencing may be a new way to treat Huntingtons. Short pieces of double-stranded RNA are used by cells to degrade RNA of a particular sequence. If a siRNA is designed to match the RNA copied from a faulty gene, then the abnormal protein product of that gene will not be produced. Medical GeneticsMedical Genetics New gene therapy approach repairs errors in messenger RNA derived from defective genes. Tec
溫馨提示
- 1. 本站所有資源如無(wú)特殊說(shuō)明,都需要本地電腦安裝OFFICE2007和PDF閱讀器。圖紙軟件為CAD,CAXA,PROE,UG,SolidWorks等.壓縮文件請(qǐng)下載最新的WinRAR軟件解壓。
- 2. 本站的文檔不包含任何第三方提供的附件圖紙等,如果需要附件,請(qǐng)聯(lián)系上傳者。文件的所有權(quán)益歸上傳用戶所有。
- 3. 本站RAR壓縮包中若帶圖紙,網(wǎng)頁(yè)內(nèi)容里面會(huì)有圖紙預(yù)覽,若沒(méi)有圖紙預(yù)覽就沒(méi)有圖紙。
- 4. 未經(jīng)權(quán)益所有人同意不得將文件中的內(nèi)容挪作商業(yè)或盈利用途。
- 5. 人人文庫(kù)網(wǎng)僅提供信息存儲(chǔ)空間,僅對(duì)用戶上傳內(nèi)容的表現(xiàn)方式做保護(hù)處理,對(duì)用戶上傳分享的文檔內(nèi)容本身不做任何修改或編輯,并不能對(duì)任何下載內(nèi)容負(fù)責(zé)。
- 6. 下載文件中如有侵權(quán)或不適當(dāng)內(nèi)容,請(qǐng)與我們聯(lián)系,我們立即糾正。
- 7. 本站不保證下載資源的準(zhǔn)確性、安全性和完整性, 同時(shí)也不承擔(dān)用戶因使用這些下載資源對(duì)自己和他人造成任何形式的傷害或損失。
最新文檔
- 探索化學(xué)奧秘:初中化學(xué)實(shí)驗(yàn)設(shè)計(jì)與探究教學(xué)大綱
- 在線教育平臺(tái)課程研發(fā)手冊(cè)
- 農(nóng)業(yè)項(xiàng)目立項(xiàng)申請(qǐng)報(bào)告怎么寫
- 部門間往來(lái)文書范例與指南
- 農(nóng)業(yè)現(xiàn)代化智能種植大數(shù)據(jù)分析平臺(tái)
- 三農(nóng)產(chǎn)品冷鏈物流運(yùn)作手冊(cè)
- 基坑支護(hù)工程安全施工方案
- 三農(nóng)產(chǎn)業(yè)發(fā)展規(guī)劃作業(yè)指導(dǎo)書
- 新能源汽車充電樁前景
- 酒店財(cái)務(wù)管理的技巧和要點(diǎn)作業(yè)指導(dǎo)書
- 《擠壓機(jī)械與設(shè)備》課件
- 天龍八部礦石分布圖
- 多相流反應(yīng)器強(qiáng)化技術(shù)
- 《非暴力溝通》分享
- 醫(yī)院院長(zhǎng)在2023年全院職工代表大會(huì)閉幕會(huì)上的講話
- 五通一平的施工方案
- 粉煤灰檢測(cè)報(bào)告
- 《Python程序設(shè)計(jì)(第3版)》教學(xué)大綱(參考)
- 廣西的地理發(fā)展介紹ppt下載
- 深靜脈血栓形成的診斷和治療指南(第三版)
- 軟件工程導(dǎo)論課件(第六版)(張海潘編著)(1-13章)
評(píng)論
0/150
提交評(píng)論